Clinical Trial Search

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 4; 10; 3; 13 participants

Primary: Overall Survival — 47 percentage of participants

Primary: Confirmed Biochemical Recurrence (BCR)-Free Rate at Month 24 — 100 Percentage of participants

Primary: Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF) — -8.4 percent change from screening visit — p=0.425

Primary: Mean Change From Baseline to Visit 11 in Total Fibrosis (%) on Log Scale, Comparing the Histology of Muscle Biopsies — -0.017; -0.054 log[percentage of total fibrosis]…

Primary: The Young Adult Alcohol Consequences Questionnaire — -4.48; -4.63 outcome score minus baseline score

Primary: Complete Pathologic Response Rate — 6 Participants

Primary: Freedom From Death or Hemocompatibility Related Adverse Events (Stroke, Device Thrombosis, Bleeding, Aortic Root Thrombus, and Arterial Non-CNS Thromboembolism) — 16; 12…

Primary: Relative Change in Body Weight (%) — 0.033 Percent Change

Primary: Smoking Cessation - Available Data — 15; 19 Participants

Primary: Number of Adult Participants With Solicited Local Adverse Events (AEs) for 7 Days Post First Vaccination — 10; 5; 20 Participants

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study — 92.9 percentage of participants

Primary: Change in Pulse Oximetry During the Baseline Visit — -0.17; -0.33 percentage of oxygen saturation

Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants

Primary: Prostate Specific Antigen (PSA) Progression Free Survival — 85.3 percentage of participants